HighVista Strategies LLC Purchases New Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

HighVista Strategies LLC acquired a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 113,550 shares of the company’s stock, valued at approximately $2,670,000. Spyre Therapeutics accounts for 1.0% of HighVista Strategies LLC’s holdings, making the stock its 29th largest holding. HighVista Strategies LLC owned 0.28% of Spyre Therapeutics at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of SYRE. Amalgamated Bank purchased a new stake in Spyre Therapeutics in the second quarter worth about $28,000. Quest Partners LLC purchased a new stake in shares of Spyre Therapeutics in the 2nd quarter worth approximately $36,000. SG Americas Securities LLC bought a new position in Spyre Therapeutics during the 2nd quarter valued at approximately $130,000. Carlyle Group Inc. purchased a new position in Spyre Therapeutics during the second quarter valued at $227,000. Finally, Profund Advisors LLC purchased a new position in shares of Spyre Therapeutics in the 2nd quarter worth about $296,000. 80.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wedbush began coverage on shares of Spyre Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $45.00 price objective on the stock. Evercore ISI assumed coverage on shares of Spyre Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating on the stock. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $43.43.

Spyre Therapeutics Price Performance

Shares of NASDAQ SYRE opened at $30.17 on Monday. The stock has a market capitalization of $1.22 billion, a P/E ratio of -0.42 and a beta of 2.92. Spyre Therapeutics, Inc. has a 1-year low of $8.43 and a 1-year high of $47.97. The business’s 50 day moving average is $27.99 and its two-hundred day moving average is $31.89.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.04. As a group, equities research analysts anticipate that Spyre Therapeutics, Inc. will post -3.68 earnings per share for the current fiscal year.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).